Newsfeeds Archive - Page 401 of 19074

1 minute read

News

Accelera By Cummins, Daimler Truck And PACCAR Complete Battery Joint Venture Transaction To Form Amplify Cell Technologies And Names Kel Kearns As The New CEO

June 4, 8:20 AM

Accelera by Cummins, Daimler Trucks & Buses US Holding LLC and PACCAR have completed the formation of their joint venture, now known as Amplify Cell Technologies, to localize battery cell production and the battery

CMI

2 minute read

Citi Trends Down After Q1 Results – Here’s Why

By Nabaparna Bhattacharya

June 4, 8:15 AM

Citi Trends' Q1 results, featuring mixed earnings and a lowered FY24 outlook, prompt drop in premarket trading.

CTRN

1 minute read

Equillium Announces Topline Data From Phase 2 Study Of EQ101 In Alopecia Areata; 20% Of All Subjects That Completed The 24-week Treatment Period Achieved SALT ≤ 20; EQ101 Was Well Tolerated In Subjects With Alopecia Areata With No Serious Adverse Event…

By Benzinga Newsdesk

June 4, 8:15 AM

20% of all subjects that completed the 24-week treatment period achieved SALT ≤ 2029% of completed subjects with moderate to severe disease (baseline SALT 35 to <95) achieved SALT ≤ 20EQ101 was well tolerated in

2 minute read

As Nvidia Closes In On Apple’s Market Cap, Munster Explains Why Cupertino Could Generate Better Returns Over Next Year

By Shanthi Rexaline

June 4, 8:13 AM

The view is in line with his previous prediction that the AI bubble will last for about three to five years.

AAPL

1 minute read

News

Aon Appoints Edmund Reese To Serve As Next CFO, Effective July 29, 2024

By Benzinga Newsdesk

June 4, 8:12 AM

Reese will bring more than 25 years of financial leadership at large public companies in the financial services, payments and technology sectors, most recently as CFO of Broadridge Financial SolutionsAon CFO Christa

AON

1 minute read

Cue Biopharma Presents Updated Data From Phase 1 Trial of CUE-101 In Recurrent/Metastatic HPV+ Head And Neck Cancer At ASCO 2024

By Benzinga Newsdesk

June 4, 8:10 AM

Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and

CUE

1 minute read

Bio-Path Holdings Announces $4M Private Placement Of 1,809,955 Shares Of Its Common Stock, Series A Warrants To Purchase Up To 1,809,955 Shares Of Common Stock And Short-Term Series B Warrants To Purchase Up To 1,809,955 Shares Of Common Stock At A Pur…

By Benzinga Newsdesk

June 4, 8:08 AM

Bio-Path Holdings, Inc. (NASDAQ:BPTH) ("Bio-Path" or the "Company"), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted

BPTH